Discovery & Browsing

One score to rank the whole proteome — and three lenses to explore it.

With well over a hundred thousand isoforms in the knowledgebase, the hard part isn't computing consequences — it's finding the ones that matter. The Discovery Index pre-computes a single Structural Impact Score (SIS) for every isoform, so the entire proteome can be ranked and filtered in real time to surface the highest-impact splice events.

The Structural Impact Score (SIS)

The SIS is a normalised 0–100 composite of five biological axes. Each axis is mapped to a sub-score between 0 and 1 with a saturating function, then combined with fixed weights that sum to 100. Because every axis is bounded, no single event type can dominate the ranking, and the number is directly interpretable — an isoform scoring 62 carries roughly 62 % of the maximum evidence for structural consequence tracked in the knowledgebase.

Step 1 — weighted composite (0–100)
base = 30·sdomain + 20·slength + 20·sneo + 15·snmd + 15·sptm

Each si ∈ [0, 1] (see the axes below); the weights sum to 100, so base is bounded 0–100.

Step 2 — confidence temper
SIS = base × (0.7 + 0.3 · pLDDT / 100)

The model's mean pLDDT scales the score by a factor of 0.70–1.00: low-confidence models are discounted but never zeroed, so a real domain loss on a lower-confidence novel isoform stays visible while genuine noise is down-weighted.

AxisWeightSub-score (0–1)What it captures
Domain disruption301 − 0.4^(lost + 0.5·gained)Loss of a conserved Pfam domain is the strongest signal of functional disruption. The term saturates (1 lost → 0.60, 2 → 0.84), so an isoform that sheds many domains can't dominate the ranking.
Length change20min(|Δlen| / 150, 1)A proxy for gross structural change, and the only structural signal available for novel isoforms with no annotated Pfam domain. Saturates at a 150-aa change relative to the canonical.
Neoantigen priority20P1→1 · P2→0.75 · P3→0.5 · P4→0.25The best neoepitope priority tier per isoform (presentation consensus × immunogenicity) — a P1 hit contributes full weight, a P4 a quarter.
NMD fate15target→1, else→0Transcripts predicted to be degraded by nonsense-mediated decay likely never yield a stable protein — a strong regulatory consequence.
PTM accessibility15lost→1 · exposed/buried→0.6Deleting a post-translational-modification site outweighs merely repositioning it, where the residue is retained but its solvent accessibility changes.
Reading the score
< 20Lowcanonical or near-canonical isoforms cluster here.
20–40Moderatea single clear perturbation (one lost domain, or NMD targeting).
40–60Highseveral converging lines of evidence — strong candidates for follow-up.
≥ 60Severemultiple domains lost plus NMD / neoantigen / PTM disruption on a confident structure.

Exploring the Knowledgebase

Three complementary lenses open the same data from different angles, each reachable from the site header. They share the underlying models but rank and filter for a different question.

Impact Explorer

Ranks every isoform proteome-wide by its Structural Impact Score. Filter by impact profile and structural confidence, then open any row for the full isoform page.

Open the explorer →
Neoepitope Atlas

A proteome-wide table of splice-junction neoantigens, ranked into P1–P4 priority tiers with filters for HLA allele, binding, and junction type.

Drug–Isoform Atlas

Ranks drugged genes by how much their splicing subtracts from each drug's binding pocket — preserved, disrupted, or lost.

Impact profiles

The Impact Explorer ships with preset filters that answer common questions in one click, on top of the free sliders for structural confidence and isoforms-per-gene:

AllNo filter — every isoform, ranked by impact score.
High ConfidenceOnly isoforms with mean pLDDT ≥ 70, where the structural prediction is reliable.
NMD TargetsTranscripts flagged as NMD targets — likely never translated.
Domain LossAt least one Pfam domain lost relative to the canonical protein.
NeoantigensCarrying at least one ranked, presented neoepitope (priority tier P1–P4).
PTM DisruptedDeleting or altering the accessibility of a PTM site.